This protocol outlines a planned Cochrane Review to evaluate the safety and efficacy of beta-blockers and RAAS inhibitors for patients with heart failure with preserved ejection fraction.
Systematic Review
Do beta-blockers, ACEIs, ARBs, MRAs, and ARNIs improve safety and efficacy in patients with heart failure with preserved ejection fraction?
This is a protocol for a Cochrane Review to evaluate the safety and efficacy of neurohormonal inhibitors in HFpEF.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the safety and efficacy of beta‐blockers (BBs), angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor antagonists (ARBs), mineralocorticoid receptor antagonists (MRAs), and angiotensin receptor neprilysin inhibitors (ARNIs) for the treatment of patients with heart failure (HF) with preserved ejection fraction (HFpEF).
Lumbers et al. (Mon,) conducted a systematic review in chronic heart failure with preserved ejection fraction (HFpEF). beta-blockers (BBs), angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor antagonists (ARBs), mineralocorticoid receptor antagonists (MRAs), and angiotensin receptor neprilysin inhibitors (ARNIs) was evaluated on safety and efficacy. This protocol outlines a planned Cochrane Review to evaluate the safety and efficacy of beta-blockers and RAAS inhibitors for patients with heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: